Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yuan Mi

Showing results (81-90 of 85) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 85 results.
Molecular Biology Reports|November 25, 2010
IL-6 -174G>C polymorphism and cancer risk: a meta-analysis involving 29,377 cases and 37,739 controlsBin Xu, Xiao-Bing Niu, Zi-Dun Wang, et al.
Plos One|January 11, 2017
Discovery and Molecular Basis of a Diverse Set of Polycomb Repressive Complex 2 Inhibitors Recognition by EEDLing Li, Hailong Zhang, Man Zhang, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 14, 2012
Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferationWei Qi, HoMan Chan, Lin Teng, et al.
Journal of Medicinal Chemistry|January 17, 2017
Discovery of First-in-Class, Potent, and Orally Bioavailable Embryonic Ectoderm Development (EED) Inhibitor with Robust Anticancer EfficacyYing Huang, Jeff Zhang, Zhengtian Yu, et al.
Journal of Medicinal Chemistry|March 30, 2022
Discovery of the Clinical Candidate MAK683: An EED-Directed, Allosteric, and Selective PRC2 Inhibitor for the Treatment of Advanced MalignanciesYing Huang, Martin Sendzik, Jeff Zhang, et al.
Pageof 9

Showing results (81-90 of 85) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 85 results.
Molecular Biology Reports|November 25, 2010
IL-6 -174G>C polymorphism and cancer risk: a meta-analysis involving 29,377 cases and 37,739 controlsBin Xu, Xiao-Bing Niu, Zi-Dun Wang, et al.
Plos One|January 11, 2017
Discovery and Molecular Basis of a Diverse Set of Polycomb Repressive Complex 2 Inhibitors Recognition by EEDLing Li, Hailong Zhang, Man Zhang, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 14, 2012
Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferationWei Qi, HoMan Chan, Lin Teng, et al.
Journal of Medicinal Chemistry|January 17, 2017
Discovery of First-in-Class, Potent, and Orally Bioavailable Embryonic Ectoderm Development (EED) Inhibitor with Robust Anticancer EfficacyYing Huang, Jeff Zhang, Zhengtian Yu, et al.
Journal of Medicinal Chemistry|March 30, 2022
Discovery of the Clinical Candidate MAK683: An EED-Directed, Allosteric, and Selective PRC2 Inhibitor for the Treatment of Advanced MalignanciesYing Huang, Martin Sendzik, Jeff Zhang, et al.
Pageof 9